Retraction notice to "High-level expression and purification of recombinant huGM-CSF(9-127)/IL-6(29-184) fusion protein in Escherichia coli" [Protein Express. Purif. 42 (2005) 278-285] (DOI:10.1016/j.pep.2005.04.007);High-level expression and purification of recombinant huGM-CSF (9-127)/IL-6 (29-184) fusion protein in Escherichia coil

Protein Expression and Purification

Volumn 42, Issue 2, 2005, Pages 278-285

  Qiang ming, Sun ^a   Hong chao, Jiang ^a   Wei ming, Xu ^a   Xin, Liu ^a   Chang bai, Dai ^a   Mao sheng, Sun ^a  

^a INSTITUTE OF MEDICAL BIOLOGY   (China)

Author keywords

Expression; Fusion protein; Granulocyte macrophage colony stimulating factor; Interleukin 6; Purification

Indexed keywords

ESCHERICHIA; ESCHERICHIA COLI;

EID: 22244492022     PISSN: 10465928     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pep.2006.09.019     Document Type: Erratum

References (30)

1. E. Bruno, R.A. Briddell, R.J. Cooper, and R. Hoffman Recombinant GM-CSF/IL-3 fusion protein: its effect on in vitro human megakaryocytopoiesis Exp. Hematol. 20 1992 494 499
2. S. Grant, R. Traylor, and G.R. Pettit Modulation by bryostatin 1 of the in vitro radioprotective effects of the GM-CSF/IL-3 fusion protein, PIXY 321, on normal human myeloid progenitors Cytokine 5 1993 490 497
3. A. Coscarella, C. Carloni, and R. Liddi Production of recombinant human GM-CSF-EPO hybrid proteins: in vitro biological characterization Eur. J. Haematol. 59 1997 238 246
4. E. Galun, E. Zeira, and O. Pappo Liver regeneration induced by a designer human IL-6/sIL-6R fusion protein reverses severe hepatocellular injury FASEB J. 14 2000 1979 1987
5. T. Takizawa, M. Yanagisawa, and W. Ochiai Directly linked soluble IL-6 receptor-IL-6 fusion protein induces astrocyte differentiation from neuroepithelial cells via activation of STAT3 Cytokine 13 2001 272 279
6. J.A. O'Shaughnessy, A. Tolcher, and D. Riseberg Prospective, randomized trial of 5-fluorouracil, leucovorin, doxorubicin, and cyclophosphamide chemotherapy in combination with the interleukin-3/granulocyte-macrophage colony-stimulating factor (GM-CSF) fusion protein (PIXY321) versus GM-CSF in patients with advanced breast cancer Blood 87 1996 2205 2211
7. L.L. Miller, E.L. Korn, D.S. Stevens, and J.E. Janik Abrogation of the hematological and biological activities of the interleukin-3/granulocyte- macrophage colony-stimulating factor fusion protein PIXY321 by neutralizing anti-PIXY321 antibodies in cancer patients receiving high-dose carboplatin Blood 93 1999 3250 3258
8. S.E. Jones, P. Khandelwal, and K. McIntyre Randomized, double-blind, placebo-controlled trial to evaluate the hematopoietic growth factor PIXY321 after moderate-dose fluorouracil, doxorubicin, and cyclophosphamide in stage II and III breast cancer J. Clin. Oncol. 17 1999 3025 3032
9. J. Neumunaitis, J.W. Singer, and C.D. Buckner Use of recombinant human granulocyte-macrophage colony stimulating factors in graft failure after bone marrow transplantation Blood 76 1990 245 253
10. S. Nand, R. Bayer, and R.A. Prinz Granulocyte-macrophage colony stimulating factors for the treatment of drug induced agranulocytosis Am. J. Hematol. 37 1991 267 269
11. C. Baxevanis, N. Tsavaris, and S. Papadhimitriou Granulocyte-macrophage colony-stimulating factor improves immunological parameters in patients with refractory solid tumours receiving second-line chemotherapy: correlation with clinical responses Eur. J. Cancer 33 1997 1202 1208
12. S. Jones, M. Schottstaedt, and L. Duncan Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer J. Clin. Oncol. 14 1996 2976 2983
13. M. Mumcuoglu, and S. Slavin Enhancement of hematopoietic reconstitution with recombinant cytokines: effect of huIL-6 in combination with rhGM-CSF and rhIL-3 on unmodified or T cell-depleted bone marrow J. Hematother. 8 1999 247 253
14. K. Imrie, B. Sheridan, and R. Colwill A phase I study of interleukin-6 after autologous bone marrow transplantation for patients with poor prognosis Hodgkin's disease Leuk. Lymphoma 25 1997 555 563
15. V.D. Hondt, Y. Humblet, and T. Guillaume Thrombopoietic effects and toxicity of IL-6 in patients with ovarian cancel before and after chemotherapy: a multicentric placebo-controlled, randomized phase Ib study Blood 85 1995 2347 2353
16. G.J. Veldhuis, P.H. Willemse, and D.T. Sleijfer Toxicity and efficacy of escalating dosages of recombinant human interleukin-6 after chemotherapy in patients with breast cancer or non-small-cell lung cancer J. Clin. Oncol. 13 1995 2585 2593
17. F. Bracho, M.D. Krailo, and V. Shen A phase I clinical, pharmacological, and biological trial of interleukin 6 plus granulocyte-colony stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent/refractory solid tumors: enhanced hematological responses but a high incidence of grade III/IV constitutional toxicities Clin. Cancer Res. 7 2001 58 67
18. R.A. Nash, S. Burstein, and R. Storb Thrombocytopenia in dogs induced by granulocyte-macrophage colony-stimulating factor: increased destruction of circulating platelets Blood 86 1995 1765 1775
19. D. Caracciolo, S.C. Clark, and G. Rovera Human interleukin-6 supports granulocytic differentiation of hematopoietic progenitor cells and acts synergistically with GM-CSF Blood 73 1989 666 670
20. M.R. Schipperus, P. Sonneveld, and J. Lindemans Interleukin-6 and interleukin-1 enhancement of GM-CSF-dependent proliferation of haematopoietic progenitor cells in myelodysplastic syndromes Br. J. Haematol. 77 1991 515 522
21. M.R. Walter, W.J. Cook, and S.E. Ealick Three-dimensional structure of recombinant human granulocyte-macrophage colony-stimulating factor J. Mol. Biol. 224 1992 1075 1085
22. J.P. Brakenhoff, M. Hart, and L.A. Aarden Analysis of human IL-6 mutants expressed in E. coli: biologic activities are not affected by deletions of amino acid 1-28 J. Immunol. 143 1989 1175 1182
23. T. Hirano Interleukin 6 and its receptor: ten years later Int. Rev. Immunol. 16 1998 249 284
24. G.G. Wong, J.S. Witek, and P.A. Temple Human GM-CSF: molecular cloning of the complementary DNA and purification of the natural and recombinant proteins Science 228 1985 810 815
25. J. Cebon, N. Nicola, and M. Ward Granulocyte-macrophage colony stimulating factor from human lymphocytes. The effect of glycosylation on receptor binding and biological activity J. Biol. Chem. 265 1990 4483 4491
26. S.J. Van, S. Cayphas, and J.P. Szikora cDNA cloning of murine interleukin-HP1: homology with human interleukin 6 Eur. J. Immunol. 18 1988 193 197
27. B.M. Curtis, D.E. Williams, and H.E. Broxmeyer Enhanced hematopoietic activity of a human granulocyte/macrophage colony-stimulating factor-interleukin 3 fusion protein Proc. Natl. Acad. Sci. USA 88 1991 5809 5813
28. V. Fontaine, J. Ooms, and J. Content Mutagenesis of the human interleukin-6 fourth predicted alpha-helix: involvement of the Arg168 in the binding site Eur. J. Immunol. 24 1994 1041 1045
29. C. Nishimura, A. Watanabe, and H. Gouda Folding topologies of human interleukin-6 and its mutants as studied by NMR spectroscopy Biochemistry 35 1996 273 281
30. M.H. Werner, G.M. Clore, and A.M. Gronenborn Refolding proteins by gel filtration chromatography FEBS Lett. 345 1994 125 130